ECMO Retrieval Program: What Have We Learned So Far

被引:2
|
作者
Krasivskyi, Ihor [1 ]
Grossmann, Clara [1 ]
Dechow, Marit [1 ]
Djordjevic, Ilija [1 ]
Ivanov, Borko [2 ]
Gerfer, Stephen [1 ]
Bennour, Walid [1 ]
Kuhn, Elmar [1 ]
Sabashnikov, Anton [1 ]
Mader, Navid [1 ]
Eghbalzadeh, Kaveh [1 ]
Wahlers, Thorsten [1 ]
机构
[1] Univ Hosp Cologne, Dept Cardiothorac Surg, D-50937 Cologne, Germany
[2] Helios Hosp Siegburg, Heart Ctr, Dept Cardiothorac Surg, D-53721 Siegburg, Germany
来源
LIFE-BASEL | 2023年 / 13卷 / 01期
关键词
ECMO; cardiogenic shock; mortality; EXTRACORPOREAL MEMBRANE-OXYGENATION; CARDIOGENIC-SHOCK; OUTCOMES; SUPPORT; ADULTS;
D O I
10.3390/life13010157
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used for patients with cardiogenic shock or cardiac arrest. However, survival rates remain low. It is unclear to what extent ECMO patients benefit from the ECMO team learning curve. Therefore, we aimed to analyze our mobile ECMO program patients from the past seven years to evaluate if a learning curve benefits patients' outcomes. We analyzed 111 patients from our databank who were supported with a VA-ECMO and brought to our hospital from January 2015 to December 2021. Patients were divided into two groups: survival (n = 70) and non-survival (n = 41). As expected, complications after ECMO implantation were more severe in the non-survivor group. The incidence of thromboembolic events (p = 0.002), hepatic failure (p < 0.001), renal failure (p = 0.002), dialysis (p = 0.002) and systemic inflammatory response syndrome (SIRS, p = 0.044) occurred significantly more often compared with the survivor group. We were able to show that despite our extensive experience in terms of ECMO retrieval program the high mortality and morbidity rates stay fairly the same over the years. This displays that we have to focus even more on patient selection and ECMO indication.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Income inequality and health: What have we learned so far?
    Subramanian, SV
    Kawachi, I
    EPIDEMIOLOGIC REVIEWS, 2004, 26 : 78 - 91
  • [32] Prophages and bacterial genomics: what have we learned so far?
    Casjens, S
    MOLECULAR MICROBIOLOGY, 2003, 49 (02) : 277 - 300
  • [33] Brain tumor immunotherapy: what have we learned so far?
    Van Gool, Stefaan Willy
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [34] The hypocretins and the reward function: what have we learned so far?
    Boutrel, Benjamin
    Steiner, Nadia
    Halfon, Olivier
    FRONTIERS IN BEHAVIORAL NEUROSCIENCE, 2013, 7
  • [35] Immunotherapy in colorectal cancer: What have we learned so far?
    Sanchez-Castanon, Maria
    Er, Tze-Kiong
    Bujanda, Luis
    Herreros-Villanueva, Marta
    CLINICA CHIMICA ACTA, 2016, 460 : 78 - 87
  • [36] Sperm DNA fragmentation: What have we learned so far?
    Xie, Philip
    Cheung, Stephanie
    Kocur, Olena M.
    Rosenwaks, Zev
    Palermo, Gianpiero D.
    FERTILITY AND STERILITY, 2021, 116 (06) : 1491 - 1491
  • [37] CEREBRAL BYPASS PROCEDURES - WHAT HAVE WE LEARNED SO FAR
    HIRSH, LF
    ROMY, M
    POSTGRADUATE MEDICINE, 1983, 73 (06) : 199 - &
  • [38] Hypopharyngeal dedifferentiated liposarcoma: What we have learned so far
    Touli, Ermioni
    Manganaris, Argyrios
    Katsiki, Evangelia
    Karasmanis, Ilias
    ORAL ONCOLOGY, 2021, 123
  • [39] COVID-19: What We Have Learned So Far
    Clifford, Theresa
    JOURNAL OF PERIANESTHESIA NURSING, 2020, 35 (04) : 445 - 446
  • [40] So, what have we learned?
    Hyde, Brendan
    Ota, Cathy
    Yust, Karen-Marie
    INTERNATIONAL JOURNAL OF CHILDRENS SPIRITUALITY, 2011, 16 (03) : 195 - 196